Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227

Reprinted with permission. For the full original post, see the Medicines Law & Policy blog.

By Ellen ‘t Hoen

The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing. Continue reading ->


Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227

World Health Organization Director General Tedros Adhanom Ghebreyesus (Tedros) admonished member states at the close of this week’s special session of the WHO Executive Board charged with examining the agency’s draft work programme for 2019-2023. A trust deficit among member states leads to the multiplication of national statements, impeding efficiency, he said. Meanwhile, a number of countries called for affordable and accessible medicines, and help to manufacture generic medicines locally, while the United States pushed the role of the private sector.  Continue reading ->


Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227

World Health Organization member states’ first reactions to the secretariat-proposed draft work programme for the next five years were mixed this morning. Although many praised the effort and the vision of the programme of work, in particular its alignment with the United Nations Sustainable Development Goals, a number of countries found the programme ambitious without the needed financial backing, and sometimes straying from the core function of the organisation. Continue reading ->

The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for “strong” IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade agreements, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading ->


Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227

Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading ->


Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227

The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director.Continue reading ->


Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227

A well-represented set of experts this week held discussions on the current situation of access to vaccines, the market, the role of pharmaceutical companies, and partnerships. Vaccines were not a field much affected by patents in the past, but the situation has changed and new vaccines are now covered by intellectual property, which might constitute a barrier to access, according to speakers. Continue reading ->